Maxim Group analyst Jason Kolbert reiterated his Buy rating and $7 price target on Cytori Therapeutics, Inc. (NASDAQ: CYTX) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE